BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 27465554)

  • 1. High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer.
    Chen X; Qian D; Cheng J; Guan Y; Zhang B; Ding X; Zeng J; Chen X; Er P; Zhang F; Zhao N; Chen X; Zhao L; Yuan Z; Pang Q; Wang P
    Tumour Biol; 2016 Oct; 37(10):13489-13498. PubMed ID: 27465554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.
    Pierceall WE; Olaussen KA; Rousseau V; Brambilla E; Sprott KM; Andre F; Pignon JP; Le Chevalier T; Pirker R; Jiang C; Filipits M; Chen Y; Kutok JL; Weaver DT; Ward BE; Soria JC
    Ann Oncol; 2012 Sep; 23(9):2245-2252. PubMed ID: 22269178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
    Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
    World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells.
    Ma Y; Kang S; Wu X; Han B; Jin Z; Guo Z
    Tumori; 2018 Oct; 104(5):338-343. PubMed ID: 28885675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PITX2: a promising predictive biomarker of patients' prognosis and chemoradioresistance in esophageal squamous cell carcinoma.
    Zhang JX; Tong ZT; Yang L; Wang F; Chai HP; Zhang F; Xie MR; Zhang AL; Wu LM; Hong H; Yin L; Wang H; Wang HY; Zhao Y
    Int J Cancer; 2013 Jun; 132(11):2567-77. PubMed ID: 23132660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of SPARC expression in unresectable NSCLC treated with concurrent chemoradiotherapy.
    Kurtul N; Eroglu C; Unal D; Tasdemir EA; Orhan O; Zararsiz G; Baran M; Kaplan B; Kontas O
    Asian Pac J Cancer Prev; 2014; 15(20):8911-6. PubMed ID: 25374228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer.
    Lan WG; Hao YZ; Xu DH; Wang P; Zhou YL; Ma LB
    Clin Transl Oncol; 2016 Apr; 18(4):375-80. PubMed ID: 26329292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
    Cho HJ; Kim HR; Park YS; Kim YH; Kim DK; Park SI
    Surg Oncol; 2015 Dec; 24(4):329-34. PubMed ID: 26690822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSP90B1 overexpression predicts poor prognosis in NSCLC patients.
    Xu Y; Chen Z; Zhang G; Xi Y; Sun R; Wang X; Wang W; Chai F; Li X
    Tumour Biol; 2016 Oct; 37(10):14321-14328. PubMed ID: 27599983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer.
    Huang Q; Fan J; Qian X; Lv Z; Zhang X; Han J; Wu F; Chen C; Du J; Guo M; Hu G; Jin Y
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):263-72. PubMed ID: 26319393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H; Zeng F; Xu L; Liu X; Huang Y
    Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer.
    Feng J; Zhang S; Wu K; Wang B; Wong JY; Jiang H; Xu R; Ying L; Huang H; Zheng X; Chen X; Ma S
    Mol Cancer Ther; 2016 May; 15(5):842-53. PubMed ID: 26839308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.